Advantages and pitfalls of the glycated hemoglobin A1c measurement in acute coronary syndrome: Start simple, evolve to more sophisticated
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2019Yazar
Karakurt, MustafaAçar, Burak
Özeke, Özcan
Özbay, Mustafa Bilal
Özen, Yasin
Karanfil, Mustafa
Ünal, Sefa
Yayla, Çağrı
Çay, Serkan
Maden, Orhan
Aras, Dursun
Topaloğlu, Serkan
Aydoğdu, Sinan
Gölbaşı, Zehra
Üst veri
Tüm öğe kaydını gösterKünye
Karakurt, M.Y., Açar, B., Özeke, O., Özbay, M. B., Özen, Y., Karanfil, M., Unal, S., Cay, S., Maden, O., Aras, D., Topaloğlu, S.B., Aydoğdu, S., Gölbaşı, Z. (2018). Advantages and pitfalls of the glycated hemoglobin A1c measurement in acute coronary syndrome: Start simple, evolve to more sophisticated. Angiology, 70(2), 182-184.Özet
We would like to thank Cetin et al1 for their interest in our work titled, “Association of Prediabetes With Higher Coronary Atherosclerotic Burden Among Patients With First Diagnosed Acute Coronary Syndrome”2 about the association of prediabetes with higher coronary atherosclerotic burden among patients with first diagnosed acute coronary syndrome (ACS). Cetin et al reported some concerns about the categorization of the study population using only glycated hemoglobin (HbA1c) level might be misleading and especially overdiagnosing prediabetic population.